Products for Research Use Only
RegisterLogin

Xaluritamig

CAT: 0804-HY-P990688-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P990688-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Xaluritamig (AMG-509) is a humanized bi-specific antibody targeting STEAP1 and CD3. Xaluritamig consists of two STEAP1 binding domains, a CD3e binding fragment variable domain and an Fc domain to prevent effector function. Xaluritamig binds T cells to facilitate T cell-mediated lysis. Xaluritamig can be used for the study of STEAP1-expressing prostate cancer and Ewing sarcoma[1].
CAS Number
2559056-68-5
Product Name Alternative
AMG-509
UNSPSC
12352203
Target
CD3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/xaluritamig.html
Purity
99
Molecular Weight
(173.555 kDa)
References & Citations
[1]Kelly WK, et al. Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024 Jan 12;14 (1) :76-89.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3

Alternative Products

CatalogName
T9901A-509-01Xaluritamig
GTR18612674-01Xaluritamig Antibody
DHJ76002Research Grade Xaluritamig
E55B1319Xaluritamig (Reference antibody)
GTR18696587-01Xaluritamig Human Monoclonal Antibody
A137881Xaluritamig without CD3 Biosimilar (Monoclonal, IgG1)
E33B100208Anti-STEAP1 (xaluritamig without CD3 biosimilar) mAb
TA421361Anti-STEAP1(xaluritamig without CD3 biosimilar) mAb
A137671Xaluritamig without CD3 Biosimilar (Monoclonal, IgG1, kappa)
A136209Xaluritamig Biosimilar (Monoclonal, IgG1-scFv-CH/G1-kappa)

Popular Products